Natalizumab, a highly specific alpha 4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring / Ludwig, Kappos; David, Bates; Gilles, Edan; Mefkure, Eraksoy; Antonio Garcia, Merino; Nikolaos, Grigoriadis; Hans Peter, Hartung; Eva, Havrdova; Jan, Hillert; Reinhard, Hohlfeld; Marcelo, Kremenchutzky; Olivier Lyon, Caen; Ariel, Miller; Pozzilli, Carlo; Mads, Ravnborg; Takahiko, Saida; Christian, Sindic; Karl, Vass; David B., Clifford; Stephen, Hauser; Eugene O., Major; Paul W., O'Connor; Howard L., Weiner; Michel, Clanet; Ralf, Gold; Hans H., Hirsch; Ernst Wilhelm, Radu; Per Soelberg, Sørensen; John, King. - In: LANCET NEUROLOGY. - ISSN 1474-4422. - 10:8(2011), pp. 745-758. [10.1016/s1474-4422(11)70149-1]
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
POZZILLI, Carlo;
2011
Abstract
Natalizumab, a highly specific alpha 4-integrin antagonist, is approved for treatment of patients with active relapsing-remitting multiple sclerosis (RRMS). It is generally recommended for individuals who have not responded to a currently available first-line disease-modifying therapy or who have very active disease. The expected benefits of natalizumab treatment have to be weighed against risks, especially the rare but serious adverse event of progressive multifocal leukoencephalopathy. In this Review, we revisit and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
